AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30239134 — intervention group
Group type: COMPARATOR
Intervention: No participation in the CR program (Control)
Number of subjects: 655
Study 28657378 — intervention group
Group type: EXPERIMENTAL
Intervention: QS‐Nd:YAG laser plus microneedling with vitamin C (Group A)
Number of subjects: 16
Study 28657378 — intervention group
Group type: COMPARATOR
Intervention: QS‐Nd:YAG laser alone (Group B)
Number of subjects: 16
Study 28657378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects and recurrence rates
Number of subjects: 16
Study 26614519 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL approach with two case scenarios for small group discussion
Number of subjects: 52
Study 26614519 — intervention group
Group type: COMPARATOR
Intervention: Ordinary teaching and learning (Control)
Number of subjects: 52
Study 26614519 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL approach
Number of subjects: 52
Study 23124915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based foods
Number of subjects: 20
Study 23124915 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil-based foods
Number of subjects: 20
Study 23124915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based foods and Vegetable oil-based foods
Number of subjects: 20
Study 21752394 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram + Lithium
Number of subjects: 80
Study 21752394 — intervention group
Group type: COMPARATOR
Intervention: Citalopram + Placebo
Number of subjects: 80
Study 18456528 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 150mg
Number of subjects: 0
Study 16431866 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing game equipment during recess periods
Number of subjects: 235
Study 15070004 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Williams syndrome (32 participants)
Number of subjects: 47
Study 15070004 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Williams syndrome (15 participants)
Number of subjects: 47
Study 15070004 — intervention group
Group type: COMPARATOR
Intervention: Control groups (matched for total number of errors and vocabulary ability)
Number of subjects: 47
Study 11081890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aprotinin (n = 100)
Number of subjects: 300
Study 11081890 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (n = 60)
Number of subjects: 300
Study 11081890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aprotinin and epsilon aminocaproic acid (n = 60)
Number of subjects: 300
Study 11081890 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 80)
Number of subjects: 300
Study 9477875 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 9477875 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 0
Study 8437368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure and volume-relief instrument (modified Brandt's rediffusion system)
Number of subjects: 14
Study 8437368 — intervention group
Group type: COMPARATOR
Intervention: Air inflation of endotracheal tube cuffs (Control group)
Number of subjects: 14
Study 3096350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation (60 mumol/kg daily) for seven consecutive days
Number of subjects: 10
Study 3096350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplementation)
Number of subjects: 10
Study 3096350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation
Number of subjects: 10
Study 30577048 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB-sign test
Number of subjects: 100
Study 30577048 — intervention group
Group type: COMPARATOR
Intervention: Lachman's test
Number of subjects: 100
Study 30577048 — intervention group
Group type: COMPARATOR
Intervention: Pivot shift test
Number of subjects: 100
Study 28819782 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (β-D-mannuronic acid)
Number of subjects: 0
Study 28819782 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 28819782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26554853 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 239
Study 26554853 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 239
Study 23848219 — intervention group
Group type: EXPERIMENTAL
Intervention: LST-HCTZ
Number of subjects: 176
Study 23848219 — intervention group
Group type: COMPARATOR
Intervention: LST-AML
Number of subjects: 176
Study 23027887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) + Methotrexate (MTX)
Number of subjects: 480
Study 20335153 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 123
Study 20335153 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 123
Study 20335153 — intervention group
Group type: COMPARATOR
Intervention: Iodine glycerin
Number of subjects: 123
Study 17640830 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bilateral tDCS (anodal left/cathodal right and anodal right/cathodal left)
Number of subjects: 13
Study 17640830 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study 15856430 — intervention group
Group type: COMPARATOR
Intervention: CYP1A1*2A polymorphism
Number of subjects: 1134
Study 15856430 — intervention group
Group type: COMPARATOR
Intervention: CYP1A1*2C polymorphism
Number of subjects: 1134
Study 15856430 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1*2B homozygosity
Number of subjects: 1134
Study 15856430 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1*2B homozygosity in postmenopausal women with long duration of menstruation (> 30 yrs)
Number of subjects: 1134
Study 15856430 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1*2B homozygosity in women with low waist‐to‐hip ratio
Number of subjects: 1134
Study 11919725 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11, 50 microg/kg subcutaneously daily for up to 21 days
Number of subjects: 13
Study 11919725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11919725 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11
Number of subjects: 13
Study 11252079 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide supplementation (212 mg.d-1)
Number of subjects: 32
Study 11252079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9260071 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml/kg)
Number of subjects: 42
Study 9260071 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (0.1 ml/kg)
Number of subjects: 42
Study 8504794 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 192
Study 8504794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 192
Study 8504794 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine and Phenobarbital
Number of subjects: 192
Study 3319172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 53
Study 3319172 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 53
Study 3319172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 29621042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 0.125 mg injected once
Number of subjects: 10
Study 26795064 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline Tri-Act(®) topical treatment
Number of subjects: 16
Study 26795064 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 16
Study 25008392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 10 mg
Number of subjects: 77
Study 25008392 — intervention group
Group type: COMPARATOR
Intervention: Fulranumab (1, 3, or 10 mg)
Number of subjects: 77
Study 25008392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 22825089 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise initiated at 13 weeks (group A)
Number of subjects: 0
Study 22825089 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise initiated at 20 weeks (group B)
Number of subjects: 0
Study 22825089 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study 20032964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 6 months
Number of subjects: 40
Study 20032964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMF)
Number of subjects: 40
Study 20032964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40
Study 19210877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost therapy (5-day infusion)
Number of subjects: 0
Study 19210877 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 16164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, double-blind, placebo-controlled food challenge (DBPCFC) with peanut
Number of subjects: 40
Study 10901785 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey with follow-up letter
Number of subjects: 400
Study 10901785 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey without follow-up letter
Number of subjects: 400
Study 10901785 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 400
Study 10901785 — intervention group
Group type: COMPARATOR
Intervention: Face to face interview
Number of subjects: 400
Study 10901785 — intervention group
Group type: COMPARATOR
Intervention: Home interview
Number of subjects: 400
Study 8708947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) acetate chewing gum (5.0 mg CHX acetate/piece)
Number of subjects: 14
Study 8708947 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol-containing chewing gum (1.0 g sorbitol/piece)
Number of subjects: 14
Study 8708947 — intervention group
Group type: COMPARATOR
Intervention: Xylitol-containing chewing gum (0.8 g xylitol/piece)
Number of subjects: 14
Study 8708947 — intervention group
Group type: COMPARATOR
Intervention: Regular plaque control routines
Number of subjects: 14
Study 8708947 — intervention group
Group type: COMPARATOR
Intervention: Xylitol-containing chewing gum
Number of subjects: 14
Study 2060556 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 12
Study 2060556 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 12
Study 2060556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30389590 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Position (RP) and checking breathing regularly
Number of subjects: 192
Study 30389590 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Position (RP) while re‐evaluating breathing every minute
Number of subjects: 192
Study 30389590 — intervention group
Group type: EXPERIMENTAL
Intervention: Head‐tilt‐chin‐lift technique
Number of subjects: 192
Study 27756583 — intervention group
Group type: EXPERIMENTAL
Intervention: NORCAP (vinorelbine/capecitabine)
Number of subjects: 149
Study 27756583 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMPAC (gemcitabine/paclitaxel)
Number of subjects: 149
Study 27756583 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMDOC (gemcitabine/docetaxel)
Number of subjects: 149
Study 23888342 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy with physiotherapy (TRT+PT) for 6 months
Number of subjects: 18
Study 23888342 — intervention group
Group type: COMPARATOR
Intervention: Testosterone replacement therapy alone (TRT) for 6 months
Number of subjects: 18
Study 21482968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (n=1800)
Number of subjects: 3602
Study 21482968 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI) (n=1802)
Number of subjects: 3602
Study 21482968 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 3602
Study 21482968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 3602
Study 21482968 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stent thrombosis
Number of subjects: 3602
Study 19071236 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OI
Number of subjects: 64
Study 19071236 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OI with haploinsufficiency mutations
Number of subjects: 64
Study 17631392 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 30 mg q.d.
Number of subjects: 548
Study 17631392 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen 2400 mg (800 mg t.i.d.)
Number of subjects: 548
Study 17631392 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 548
Study 15178376 — intervention group
Group type: EXPERIMENTAL
Intervention: VOE tasks with test trials only
Number of subjects: 0
Study 15178376 — intervention group
Group type: COMPARATOR
Intervention: Control results
Number of subjects: 0
Study 11732707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (noncompetitive NMDA receptor antagonist)
Number of subjects: 28
Study 11732707 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenic group
Number of subjects: 28
Study 11732707 — intervention group
Group type: COMPARATOR
Intervention: Medicated schizophrenic group
Number of subjects: 28
Study 11732707 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 28
Study 11732707 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic group (task vs. condition comparison)
Number of subjects: 28
Study 11732707 — intervention group
Group type: COMPARATOR
Intervention: Normal group (task vs. condition comparison)
Number of subjects: 28
Study 11732707 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic group (task and control conditions)
Number of subjects: 28
Study 11732707 — intervention group
Group type: COMPARATOR
Intervention: Normal group (task and control conditions)
Number of subjects: 28
Study 10874361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (120 mg/day for 28 days)
Number of subjects: 31
Study 10874361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8580704 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of unbound L-tryptophan concentrations using reverse-phase HPLC with fluorescence detection
Number of subjects: 9
Study 2526365 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 456
Study 2526365 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 456
Study 2526365 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 456
Study 2526365 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased trunk extension strength
Number of subjects: 456
Study 2526365 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved physical fitness
Number of subjects: 456
Study 2526365 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of lumbar and hip mobility
Number of subjects: 456
Study 412613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 0
Study 31529159 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more adverse events
Number of subjects: 60
Study 31529159 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent OAA stoppage
Number of subjects: 60
Study 31529159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adverse events or medication stoppage)
Number of subjects: 60
Study 29168741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine 100 mg/kg
Number of subjects: 17
Study 29168741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine 150 mg/kg
Number of subjects: 17
Study 29168741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine 200 mg/kg
Number of subjects: 17
Study 29168741 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine 150 mg/kg (young adults)
Number of subjects: 17
Study 26023914 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity intervention (150 additional minutes of exercise per week)
Number of subjects: 129
Study 26023914 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive physical activity intervention (300 additional minutes of exercise per week)
Number of subjects: 129
Study 26023914 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 23449826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib/bevacizumab
Number of subjects: 0
Study 23449826 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib monotherapy
Number of subjects: 0
Study 23449826 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 0
Study 22066891 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60)
Number of subjects: 121
Study 22066891 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61)
Number of subjects: 121
Study 22066891 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 121
Study 22066891 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 121
Study 18046544 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic blockade)
Number of subjects: 0
Study 18046544 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (selective NE reuptake inhibitor)
Number of subjects: 0
Study 18046544 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (peripheral beta-adrenergic antagonist)
Number of subjects: 0
Study 16141462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RAAS blockade (losartan and lisinopril)
Number of subjects: 6
Study 16141462 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuric patients
Number of subjects: 6
Study 16141462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiproteinuric treatment
Number of subjects: 6
Study 15576063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipanic medication
Number of subjects: 25
Study 15576063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 25
Study 15576063 — intervention group
Group type: COMPARATOR
Intervention: Normal comparison subjects
Number of subjects: 25
Study 11243292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (Group 1)
Number of subjects: 301
Study 11243292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (Group 2)
Number of subjects: 301
Study 11243292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (Group 3)
Number of subjects: 301
Study 11243292 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 301
Study 9349065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group, n = 20)
Number of subjects: 40
Study 9349065 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 25 mg without adrenaline (plain group, n = 18)
Number of subjects: 40
Study 9349065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group)
Number of subjects: 40
Study 9349065 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 25 mg without adrenaline (plain group)
Number of subjects: 40
Study 8462415 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide in oxygen
Number of subjects: 0
Study 8462415 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide in oxygen
Number of subjects: 0
Study 8462415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (both concentrations)
Number of subjects: 0
Study 8462415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oxygen)
Number of subjects: 0
Study 3950827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent green lamps (Sylvania F20T12/G)
Number of subjects: 2
Study 3950827 — intervention group
Group type: COMPARATOR
Intervention: Special blue lamps (Westinghouse F20T12/BB)
Number of subjects: 2
Study 30220508 — intervention group
Group type: EXPERIMENTAL
Intervention: SC (shear test 24h after bonding)
Number of subjects: 60
Study 30220508 — intervention group
Group type: COMPARATOR
Intervention: μTC (microtensile test 24h after bonding)
Number of subjects: 60
Study 30220508 — intervention group
Group type: EXPERIMENTAL
Intervention: μTF (microtensile test after mechanical fatigue)
Number of subjects: 60
Study 30220508 — intervention group
Group type: EXPERIMENTAL
Intervention: μTT (microtensile test after thermocycling)
Number of subjects: 60
Study 27392388 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting ethmoidal stent (SEES)
Number of subjects: 70
Study 27392388 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ethmoidectomy (EE)
Number of subjects: 70
Study 24682707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview skills curriculum (ISC), a manualized 12-week group-delivered intervention.
Number of subjects: 28
Study 24682707 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study 24349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Music classes
Number of subjects: 0
Study 24349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual arts classes
Number of subjects: 0
Study 24349171 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study 19854713 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral DHEA
Number of subjects: 60
Study 19854713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19036149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse clinic care
Number of subjects: 126
Study 19036149 — intervention group
Group type: COMPARATOR
Intervention: Home care
Number of subjects: 126
Study 17237853 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction 2 cycles paclitaxel (175 mg/m2) and carboplatin (AUC 6) followed by concomitant paclitaxel (45 mg/m2) and carboplatin (AUC 2) weekly with radiotherapy (Group A)
Number of subjects: 60
Study 17237853 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant carboplatin, paclitaxel (same doses as in Group A) and radiotherapy (Group B)
Number of subjects: 60